HCV阴性受者接受HCV阳性供肾肾移植临床研究现状

唐茂芝; 张克勤

doi:10.3969/j.issn.1674-7445.2023.02.009

HCV阴性受者接受HCV阳性供肾肾移植临床研究现状

doi: 10.3969/j.issn.1674-7445.2023.02.009

唐茂芝^,,
张克勤

400010 重庆，重庆医科大学附属第二医院泌尿肾病中心

基金项目:

国家自然科学基金面上项目 81670684

详细信息

作者简介:

通讯作者:
唐茂芝，Email：tmzm0130@163.com

中图分类号: R617, R512.6+3
计量
- 文章访问数: 193
- HTML全文浏览量: 65
- PDF下载量: 61
- 被引次数: 0
出版历程
- 收稿日期: 2022-11-09
- 网络出版日期: 2023-03-15
- 刊出日期: 2023-03-15

Status of clinical research in HCV-negative recipients undergoing kidney transplantation from HCV-positive renal allografts

Tang Maozhi^,,
Zhang Keqin

Urinary Nephropathy Center, the Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China

More Information

Corresponding author: Tang Maozhi, Email: tmzm0130@163.com

摘要

摘要: 慢性丙型肝炎病毒（HCV）感染者的抗病毒治疗已经进入直接抗病毒药物（DAA）时代，高达95%的患者可获得临床治愈，在这样的背景下，HCV感染从肾移植手术相对禁忌证逐渐变为手术适应证。然而，目前国内报道的供者或受者HCV感染肾移植数量相当有限，国外已报道的不少HCV阴性受者接受HCV阳性供肾肾移植短期随访数据证实，在DAA治疗下该类型肾移植HCV感染治愈率高，安全性良好，且短期受者生存及移植物结局理想，但目前缺乏大样本、长随访期的临床研究进一步验证HCV感染肾移植的长期安全性。本文就DAA干预下HCV阴性受者接受HCV阳性供肾的病毒学清除、移植物结局及肾移植受者DAA使用的安全性等问题进行探讨，评价这种移植方式的临床安全性和有效性，提高对HCV阳性器官安全使用的认识。
- 丙型肝炎病毒（HCV） /
- 肾移植 /
- 直接抗病毒药物（DAA） /
- 聚乙二醇干扰素 /
- 利巴韦林 /
- 持续病毒学应答 /
- 估算肾小球滤过率 /
- 移植物功能延迟恢复
Abstract: Antiviral therapy for chronic hepatitis C virus (HCV) infection has entered the era of direct antiviral agent (DAA), and up to 95% of patients could be clinically cured. Under this circumstance, HCV infection has gradually changed from relative contraindication to surgical indication for kidney transplantation. However, at present, the number of kidney transplantation from HCV-infected donors or recipients has been rarely reported in China. The short-term follow-up data of HCV-negative recipients undergoing kidney transplantation from HCV-positive renal allografts in other countries have confirmed that DAA yields high cure rate and safety in the treatment of HCV infection, and recipients could obtain favorable short-term survival and allograft outcome. However, the long-term safety of HCV-infected kidney transplantation remains to be validated by clinical trials with large sample size and long-term follow-up. In this article, the virological clearance, allograft outcome and safety of DAA use in HCV-negative recipients undergoing kidney transplantation from HCV-positive renal allografts under the intervention of DAA were investigated, aiming to evaluate clinical safety and efficacy of this pattern of kidney transplantation and deepen the understanding of safe use of HCV-positive organs.
- Hepatitis C virus (HCV) /
- Kidney transplantation /
- Direct antiviral agent (DAA) /
- Pegylated interferon /
- Ribavirin /
- Sustained virological response /
- Estimated glomerular filtration rate /
- Delayed graft function

HTML全文

下载: 全尺寸图片幻灯片

参考文献(40)

[1]	XIE Q, XUAN JW, TANG H, et al. Hepatitis C virus cure with direct acting antivirals: clinical, economic, societal and patient value for China[J]. World J Hepatol, 2019, 11(5): 421-441. DOI: 10.4254/wjh.v11.i5.421.
[2]	DAREMA M, CHOLONGITAS E, FILIOPOULOS V, et al. Efficacy and safety of new direct-acting antivirals in kidney transplant recipients with chronic hepatitis C: a single-center study[J]. Ann Gastroenterol, 2020, 33(3): 285-292. DOI: 10.20524/aog.2020.0481.
[3]	EL HELOU G, JAY C, NUNEZ M. Hepatitis C virus and kidney transplantation: recent trends and paradigm shifts[J]. Transplant Rev (Orlando), 2022, 36(1): 100677. DOI: 10.1016/j.trre.2021.100677.
[4]	LEVITSKY J, FORMICA RN, BLOOM RD, et al. The American Society of Transplantation Consensus conference on the use of hepatitis C viremic donors in solid organ transplantation[J]. Am J Transplant, 2017, 17(11): 2790-2802. DOI: 10.1111/ajt.14381.
[5]	FABRIZI F, CERUTTI R, MESSA P. An updated view on the antiviral therapy of hepatitis C in chronic kidney disease[J]. Pathogens, 2021, 10(11): 1381. DOI: 10.3390/pathogens10111381.
[6]	CANNON RM, LOCKE JE, ORANDI BJ, et al. Impact of donor hepatitis C virus on kidney transplant outcomes for hepatitis C-positive recipients in the direct-acting antiviral era: time to revise the kidney donor risk index? [J]. Transplantation, 2020, 104(6): 1215-1228. DOI: 10.1097/TP.0000000000002949.
[7]	WANG JH, GUSTAFSON SK, SKEANS MA, et al. OPTN/SRTR 2018 annual data report: hepatitis C[J]. Am J Transplant, 2020, 20(Suppl s1): 542-568. DOI: 10.1111/ajt.15679.
[8]	MAGALHÃES-COSTA P, LEBRE L, MACHADO D, et al. Lack of impact of hepatitis C virus infection on graft survival after kidney transplantation--a Portuguese single-center experience[J]. Transplant Proc, 2015, 47(4): 926-932. DOI: 10.1016/j.transproceed.2015.03.010.
[9]	COLOMBO M, AGHEMO A, LIU H, et al. Treatment with ledipasvir-sofosbuvir for 12 or 24 weeks in kidney transplant recipients with chronic hepatitis C virus genotype 1 or 4 infection: a randomized trial[J]. Ann Intern Med, 2017, 166(2): 109-117. DOI: 10.7326/M16-1205.
[10]	ZHANG J, SUN W, LIN J, et al. Long-term follow-up of HCV infected kidney transplant recipients receiving direct-acting antiviral agents: a single-center experience in China[J]. BMC Infect Dis, 2019, 19(1): 645. DOI: 10.1186/s12879-019-4217-7.
[11]	王红, 韦晓瑞. DAAs对肾移植术后丙型病毒性肝炎疗效的影响[J]. 中国继续医学教育, 2020, 12(21): 134-136. DOI: 10.3969/j.issn.1674-9308.2020.21.057. WANG H, WEI XR. Effect of DAAs on the efficacy of viral hepatitis C after renal transplantation[J]. Chin Contin Med Educ, 2020, 12(21): 134-136. DOI: 10.3969/j.issn.1674-9308.2020.21.057.
[12]	牛英, 明英姿, 佘兴国, 等. 直接抗病毒药物治疗肾移植术后丙型病毒性肝炎疗效与安全性的临床观察[J]. 器官移植, 2017, 8(1): 49-53. DOI: 10.3969/j.issn.1674-7445.2017.01.010. NIU Y, MING YZ, SHE XG, et al. Preliminary observation of clinical efficacy and safety of direct-acting antiviral agents for hepatitis C virus following renal transplantation[J]. Organ Transplant, 2017, 8(1): 49-53. DOI: 10.3969/j.issn.1674-7445.2017.01.010.
[13]	胡丽霞, 雷学忠. 直接抗病毒药物治疗肝/肾移植术后丙型肝炎疗效及安全性研究[J]. 四川大学学报(医学版), 2019, 50(5): 775-778. https://www.cnki.com.cn/Article/CJFDTOTAL-HXYK201905029.htm HU LX, LEI XZ. Efficacy and safety of direct antiviral drugs in the treatment of hepatitis C after liver/kidney transplantation [J]. J Sichuan Univ(Med Sci), 2019, 50(5): 775-778. https://www.cnki.com.cn/Article/CJFDTOTAL-HXYK201905029.htm
[14]	冯成, 杨洪吉, 侯一夫, 等. 直接抗病毒药物在肾移植丙型肝炎病毒患者中的应用[J/CD]. 实用器官移植电子杂志, 2020, 8(2): 96-100. DOI: 10.3969/j.issn.2095-5332.2020.02.005. FENG C, YANG HJ, HOU YF, et al. Application of direct antiviral drugs in patients with hepatitis C virus after renal transplantation[J/CD]. Pract J Organ Transplant (Electr Vers), 2020, 8(2): 96-100. DOI: 10.3969/j.issn.2095-5332.2020.02.005.
[15]	MOLNAR MZ, NAIR S, CSEPREKAL O, et al. Transplantation of kidneys from hepatitis C-infected donors to hepatitis C-negative recipients: single center experience[J]. Am J Transplant, 2019, 19(11): 3046-3057. DOI: 10.1111/ajt.15530.
[16]	DURAND CM, BOWRING MG, BROWN DM, et al. Direct-acting antiviral prophylaxis in kidney transplantation from hepatitis C virus-infected donors to noninfected recipients: an open-label nonrandomized trial[J]. Ann Intern Med, 2018, 168(8): 533-540. DOI: 10.7326/M17-2871.
[17]	DURAND CM, BARNABA B, YU S, et al. Four-week direct-acting antiviral prophylaxis for kidney transplantation from hepatitis C-viremic donors to hepatitis C-negative recipients: an open-label nonrandomized study[J]. Ann Intern Med, 2021, 174(1): 137-138. DOI: 10.7326/M20-1468.
[18]	KAPILA N, MENON KVN, AL-KHALLOUFI K, et al. Hepatitis C virus NAT-positive solid organ allografts transplanted into hepatitis C virus-negative recipients: a real-world experience[J]. Hepatology, 2020, 72(1): 32-41. DOI: 10.1002/hep.31011.
[19]	SISE ME, GOLDBERG DS, KORT JJ, et al. Multicenter study to transplant hepatitis C-infected kidneys (MYTHIC): an open-label study of combined glecaprevir and pibrentasvir to treat recipients of transplanted kidneys from deceased donors with hepatitis C virus infection[J]. J Am Soc Nephrol, 2020, 31(11): 2678-2687. DOI: 10.1681/ASN.2020050686.
[20]	REESE PP, ABT PL, BLUMBERG EA, et al. Twelve-month outcomes after transplant of hepatitis C-infected kidneys into uninfected recipients: a single-group trial[J]. Ann Intern Med, 2018, 169(5): 273-281. DOI: 10.7326/M18-0749.
[21]	LA HOZ RM, SANDIKÇI B, ARIYAMUTHU VK, et al. Short-term outcomes of deceased donor renal transplants of HCV uninfected recipients from HCV seropositive nonviremic donors and viremic donors in the era of direct-acting antivirals[J]. Am J Transplant, 2019, 19(11): 3058-3070. DOI: 10.1111/ajt.15496.
[22]	CONCEPCION BP, BINARI LA, SCHAEFER H, et al. Kidney transplantation from hepatitis C viremic deceased donors to aviremic recipients in a real-world setting[J]. Transplant Direct, 2021, 7(10): e761. DOI: 10.1097/TXD.0000000000001217.
[23]	POTLURI VS, GOLDBERG DS, MOHAN S, et al. National trends in utilization and 1-year outcomes with transplantation of HCV-viremic kidneys[J]. J Am Soc Nephrol, 2019, 30(10): 1939-1951. DOI: 10.1681/ASN.2019050462.
[24]	MOLNAR MZ, AZHAR A, TSUJITA M, et al. Transplantation of kidneys from hepatitis C virus-infected donors to hepatitis C virus-negative recipients: one-year kidney allograft outcomes[J]. Am J Kidney Dis, 2021, 77(5): 739-747. DOI: 10.1053/j.ajkd.2020.10.017.
[25]	SMOLDERS EJ, JANSEN AME, TER HORST PGJ, et al. Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations: a 2019 update[J]. Clin Pharmacokinet, 2019, 58(10): 1237-1263. DOI: 10.1007/s40262-019-00774-0.
[26]	European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018[J]. J Hepatol, 2018, 69(2): 461-511. DOI: 10.1016/j.jhep.2018.03.026.
[27]	MCCAULEY M, MUSSELL A, GOLDBERG D, et al. Race, risk, and willingness of end-stage renal disease patients without hepatitis C virus to accept an HCV-infected kidney transplant[J]. Transplantation, 2018, 102(4): e163-e170. DOI: 10.1097/TP.0000000000002099.
[28]	EDWARDS GC, SHIPE ME, SMITH L, et al. Exploring patient willingness to accept hepatitis C-infected kidneys for transplantation[J]. BMC Nephrol, 2020, 21(1): 473. DOI: 10.1186/s12882-020-02114-y.
[29]	ATIEMO K, BAUDIER R, CRAIG-SCHAPIRO R, et al. Factors underlying racial disparity in utilization of hepatitis C-viremic kidneys in the United States[J]. J Racial Ethn Health Disparities, 2022, DOI: 10.1007/s40615-022-01398-0[Epubahead of print].
[30]	SAINE ME, SCHNELLINGER EM, LIU M, et al. Decision-making among hepatitis C virus-negative transplant candidates offered organs from donors with HCV infection[J]. Transplant Direct, 2022, 8(8): e1341. DOI: 10.1097/TXD.0000000000001341.
[31]	LIN SH, WU KT, WANG CC, et al. HCV RNA in serum and liver samples of patients undergoing living donor liver transplantation[J]. J Int Med Res, 2021, 49(8): 3000605211034945. DOI: 10.1177/03000605211034945.
[32]	MEUNIER L, BELKACEMI M, PAGEAUX GP, et al. Patients treated for HCV infection and listed for liver transplantation in a french multicenter study: what happens at five years? [J]. Viruses, 2022, 15(1): 137. DOI: 10.3390/v15010137.
[33]	FABRIZI F, CERUTTI R, SILVA M. HCV-infected solid organ donors, direct-acting antivirals and the current challenges[J]. Expert Rev Clin Pharmacol, 2020, 13(1): 7-14. DOI: 10.1080/17512433.2020.1697677.
[34]	王宏霞, 王艳, 王琳, 等. 丙型肝炎阴性受体接受感染供体肾脏移植抗病毒治疗研究进展[J]. 中华临床感染病杂志, 2022, 15(5): 395-400. DOI: 10.3760/cma.j.issn.1674-2397.2022.05.012. WANG HX, WANG Y, WANG L, et al. Research progress on antiviral therapy in hepatitis C-negative recipients receiving kidney transplantation from infected donors[J]. Chin J Clin Infect Dis, 2022, 15(5): 395-400. DOI: 10.3760/cma.j.issn.1674-2397.2022.05.012.
[35]	邹铭南, 蔡大川. 直接抗病毒药物治疗丙型肝炎病毒感染相关严重肝病的获益[J]. 中华传染病杂志, 2020, 38(5): 320-323. DOI: 10.3760/cma.j.cn311365-20190718-00228. ZOU MN, CAI DC. Benefits of direct antiviral drugs in the treatment of hepatitis C virus infection-associated severe liver disease[J]. Chin J Infect Dis, 2020, 38(5): 320-323. DOI: 10.3760/cma.j.cn311365-20190718-00228.
[36]	黄锦妮, 江建宁, 梁丹丹, 等. 基因6型慢性丙型肝炎的流行病学特征及抗病毒疗效分析[J]. 临床肝胆病杂志, 2022, 38(4): 793-797. DOI: 10.3969/j.issn.1001-5256.2022.04.011. HUANG JN, JIANG JN, LIANG DD, et al. Epidemiological features and antiviral response of genotype 6 chronic hepatitis C[J]. J Clin Hepatol, 2022, 38(4): 793-797. DOI: 10.3969/j.issn.1001-5256.2022.04.011.
[37]	KANG Q, XU J, LUO H, et al. Direct antiviral agent treatment leads to rapid and significant fibrosis regression after HCV eradication[J]. J Viral Hepat, 2021, 28(9): 1284-1292. DOI: 10.1111/jvh.13558.
[38]	LI J, WU V, PAN CQ. Direct antiviral therapy for hepatitis C cirrhotic patients in liver transplantation settings: a systematic review[J]. Hepatol Int, 2022, 16(5): 1020-1031. DOI: 10.1007/s12072-022-10380-1.
[39]	ATAMLA M, KHOURY J, DABBAH I, et al. Direct antiviral agents for chronic hepatitis C virus infection improve health-related quality of life significantly in the long term[J]. Clin Exp Hepatol, 2021, 7(3): 258-263. DOI: 10.5114/ceh.2021.109192.
[40]	廖宝林, 李凌华, 钟活麟, 等. 直接抗病毒药物治疗HIV/HCV合并感染患者长期疗效及肝纤维化改变[J]. 中华肝脏病杂志, 2021, 29(8): 776-780. DOI: 10.3760/cma.j.cn501113-20201228-00682. LIAO BL, LI LH, ZHONG HL, et al. Long-term therapeutic effects and liver fibrosis changes with direct-antiviral therapy in HIV/HCV co-infected patients[J]. Chin J Hepatol, 2021, 29(8): 776-780. DOI: 10.3760/cma.j.cn501113-20201228-00682.